Failed 2024

    Onco

    In Indian health-tech, the exit is the largest hospital chain, not the IPO. Build for strategic value from year two.

    TL;DR — Failure Post-Mortem

    Onco was a Health Tech / Cancer Care startup founded in 2018 in India. It raised $7M before collapsing in 2024 — 6 years of runway burned. IdeaProof's AI Failure Score: 54/100, driven by sub-scale patient acquisition led to a quiet strategic acquisition by apollo hospitals. The shutdown affected employees, investors, and the broader Health Tech / Cancer Care ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did Onco fail?

    Onco failed in 2024 after 6 years of operation, losing $7M in raised capital. The root cause was sub-scale patient acquisition led to a quiet strategic acquisition by apollo hospitals. Key lesson: In Indian health-tech, the exit is the largest hospital chain, not the IPO. Build for strategic value from year two.

    Verifiable facts
    Sourced
    Founded → Closed

    2018 → 2024

    Funding Raised

    $7M

    Industry

    Health Tech / Cancer Care

    Country

    India

    IdeaProof AI Failure Score

    54/100
    Market Fit Risk
    55
    Burn Rate Risk
    60
    Founder Risk
    45

    What Happened: The Timeline

    🚀

    2018

    Onco founded in India. Positioned in health tech / cancer care.

    💰

    2018-2020

    Raises $7M from Accel, Better Capital, angels.

    ⚠️

    2023

    Warning signs emerge: patient cac too high for out-of-pocket cancer care.

    💀

    2024

    Shutdown announced. Root cause: sub-scale patient acquisition led to a quiet strategic acquisition by apollo hospitals.

    Root Causes

    Onco was an Accel-backed cancer care coordination platform founded in 2018 in Bengaluru, offering second opinions, treatment planning and remote monitoring for cancer patients across India. In December 2024 Apollo Hospitals quietly acquired Onco in what was disclosed only in mid-2025 via CXO Digital Pulse reporting. The deal folded Onco's technology and clinician network into Apollo's oncology practice; financial terms were undisclosed but sources indicated a modest strategic price consistent with Onco's ~$7M raised. Onco is the archetype of the Indian health-tech soft landing: strong product, thin revenue, hospital chain absorbs.

    Causal Chain

    Derived · heuristic

    This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.

    Contributing factors
    • Patient CAC too high for out-of-pocket cancer care
    • No insurance reimbursement lever in India
    • Hospital chains bypass startups on patient flow
    • Small ticket size vs oncology capex
    Proximate cause

    2023: Warning signs emerge: patient cac too high for out-of-pocket cancer care.

    Terminal event

    2024: Shutdown announced. Root cause: sub-scale patient acquisition led to a quiet strategic acquisition by apollo hospitals.

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Onco's profile. Sources are third-party; we do not restate them as our own claims.

    ~70%
    industry

    of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.

    Rock Health State of Digital Health (2023)
    ~90%
    all

    of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.

    Startup Genome / CB Insights aggregate (2024)
    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)
    ~35%
    stage

    of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.

    CB Insights Venture Capital Funnel (2023)

    Key Lessons Learned

    1. Patient CAC too high for out-of-pocket cancer care

    Patient CAC too high for out-of-pocket cancer care — a recurring pattern across health tech / cancer care failures. Validate this risk before you scale.

    2. No insurance reimbursement lever in India

    No insurance reimbursement lever in India — a recurring pattern across health tech / cancer care failures. Validate this risk before you scale.

    3. Hospital chains bypass startups on patient flow

    Hospital chains bypass startups on patient flow — a recurring pattern across health tech / cancer care failures. Validate this risk before you scale.

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Onco.

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.